Connect with us

Intended for US Healthcare Professionals Only.Important Safety Information

With IXINITY®, your patients define their IXperience™

Patients can create an IXperience with their factor, their community, and a company that’s got their back.

Factor It Forward

With FACTOR IT FORWARD, 10% of IXINITY used is donated to nines in the United States who can’t afford to be without it.

The hemophilia community has always taken care of its own. FACTOR IT FORWARD continues the tradition by helping you give back here in the United States.

  • For every 10 IU of IXINITY used, 1 IU is donated to treatment centers for compassionate use programs
  • There’s no limit on the number of IUs donated.
  • And you can take part to make your mark and Sign the 9 to Factor It Forward.

We’ve partnered with AmeriCares, the nonprofit global health organization that delivers medical aid to people in need.

Sign up your HTC today to receive factor. Go to FactorItForward.com.

A 9 who infuses 4,000 IU twice a week

arrow right

helps FACTOR IT FORWARD donate more than 40,000 units a year.

caret left icon

See how FACTOR IT FORWARD can benefit your organization by helping patients who can’t afford to be without factor.

MEET A CORE CONNECTIONS TEAM MEMBER

Helps patients get the answers they need.

Patients will have access to Core Connections for answers to any questions they may have about IXINITY or the IXperience™. By calling 1-855-IXINITY (1-855-494-6489), patients can learn how Core Connections can aid with:

  • Signing up for the IXINITY FREE trial
  • Filling out forms, step-by-step
  • Getting started on treatment
  • Connecting with a doctor or pharmacy
  • Finding solutions to reimbursement issues
  • Customizing their IXperience
border

CONNECT WITH THE REIMBURSEMENT EXPERT

Committed to getting you covered.

Reimbursement specialists are dedicated to helping you and your patients solve any insurance issue so that you can focus on what really matters. Call 1-855-IXINITY (1-855-494-6489) to learn how reimbursement specialists:

  • Collect and organize information to process a patient’s coverage
  • Investigate benefits and determine what kind of assistance is required
  • Speak with patients and doctors’ offices to confirm individual needs
  • Work with insurance companies to resolve any issues you or your patients may encounter
  • Build relationships with hemophilia B patients and healthcare providers to ensure a seamless experience
Call Core Connections at 1-855-494-6489

+ MORE

- LESS

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: IXINITY® [coagulation factor IX (recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

CONTRAINDICATIONS: IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions, including anaphylaxis, has occurred with IXINITY. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions.

Thromboembolism has occurred with IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis).

Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts.

The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information.

You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes
No